• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    PolarityTE Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8/18/23 4:54:40 PM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PTE alert in real time by email
    0001076682 false --12-31 POLARITYTE, INC. 0001076682 2023-08-18 2023-08-18 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): August 18, 2023

     

    REGENETP, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-32404   06-1529524

    (State or other jurisdiction

    of incorporation)

     

    (Commission

    File Number)

     

    (IRS Employer

    Identification No.)

     

    1960 S. 4250 West, Salt Lake City, UT 84104

    (Address of principal executive offices and zip code)

     

    Registrant’s telephone number, including area code: (800) 560-3983

     

    PolarityTE, Inc.

     

    (Former name or former address, if changed since last report.)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol   Name of each exchange on which registered
    Common Stock, Par Value $0.001   PTE   Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐.

     

     

     

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    Resignation of Chief Financial Officer

     

    On August 18, 2023, Jacob Patterson, Chief Financial Officer of RegenETP, Inc. (formerly known as PolarityTE, Inc.), a Delaware corporation (the “Company”), informed the Company of his decision to resign effective immediately in order to pursue other opportunities.

     

    Appointment of Director

     

    On August 18, 2023, the Board of Directors (the “Board”) of the Company appointed Richard Hague, who currently serves as the Chief Executive Officer of the Company, to serve as a director effective immediately. Mr. Hague will continue to serve as Chief Executive Officer of the Company.

     

    There are no arrangements or understandings between Mr. Hague and any other person pursuant to which he was elected as a director of the Company. There are no family relationships between Mr. Hague and any director, executive officer, or any person nominated or chosen by the Company to become a director or executive officer. There are no related person transactions (within the meaning of Item 404(a) of Regulation S-K promulgated by the Securities and Exchange Commission) between Mr. Hague and the Company.

     

    Resignation of Directors

     

    On August 18, 2023, Willie C. Bogan, Peter A. Cohen, and David Seaburg resigned as members of the Board effective immediately, including as a member of all Board committees of which they are a member. The resignations of such directors was not due to any disagreement with the Company or the Board on any matter relating to the Company’s operations, policies, or practices. At the time of their resignations, Mr. Bogan served on the Compensation Committee and the Nominating and Governance Committee (including as chairperson); and Mr. Cohen served on the Audit Committee and the Compensation Committee (including as chairperson) of the Board.

     

    Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

     

    Amendment to Certificate of Incorporation

     

    On August 18, 2023, the Company filed a Certificate of Amendment (the “Certificate Amendment”) to the Third Restated Certificate of Incorporation of the Company reflecting the change of the Company’s name to “RegenETP, Inc.” The foregoing summary description of the Certificate Amendment is qualified in its entirety by reference to the full text of the Certificate Amendment, which is attached hereto as Exhibit 3.1 and is incorporated by reference herein.

     

    Amendment to Bylaws

     

    On August 18, 2023, the Company adopted an Amendment to its Amended and Restated Bylaws (the “Bylaw Amendment”) to reflect the change of the Company’s name to “RegenETP, Inc.” The foregoing summary description of the Bylaw Amendment is qualified in its entirety by reference to the full text of the Bylaw Amendment, which is attached hereto as Exhibit 3.2 and is incorporated by reference herein.

     

    Item 9.01. Financial Statements and Exhibits

     

    (d) Exhibits.

     

    Exhibit No.   Description
    3.1   Certificate of Amendment to the Third Restated Certificate of Incorporation of PolarityTE, Inc., dated as of August 18, 2023.
    3.2   Amendment to the Amended and Restated Bylaws of PolarityTE, Inc., dated as of August 18, 2023
    104   Cover Page Interactive Data File, formatted in Inline XBRL

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

      POLARITYTE, INC.
       
    Dated: August 18, 2023 /s/ Richard Hague
      Richard Hague  
      Chief Executive Officer

     

     

    Get the next $PTE alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PTE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PTE
    SEC Filings

    View All

    PolarityTE Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

    8-K - POLARITYTE, INC. (0001076682) (Filer)

    8/18/23 4:54:40 PM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form NT 10-Q filed by PolarityTE Inc.

    NT 10-Q - POLARITYTE, INC. (0001076682) (Filer)

    8/15/23 4:40:32 PM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PolarityTE Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

    8-K - POLARITYTE, INC. (0001076682) (Filer)

    8/15/23 4:30:36 PM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PTE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Dyer Jeffrey Hansen was granted 42,986 shares, increasing direct ownership by 3,177% to 44,339 units

    4 - POLARITYTE, INC. (0001076682) (Issuer)

    1/30/23 4:30:42 PM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 3: New insider Dyer Jeffrey Hansen claimed ownership of 1,353 shares

    3 - POLARITYTE, INC. (0001076682) (Issuer)

    1/30/23 4:15:33 PM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4: Nolet Chris decreased direct ownership by 72% to 14,403 units

    4 - POLARITYTE, INC. (0001076682) (Issuer)

    1/17/23 4:30:29 PM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PTE
    Leadership Updates

    Live Leadership Updates

    View All

    PolarityTE Announces Resignation of Jeff Dyer from its Board of Directors

    SALT LAKE CITY, Sept. 8, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that Jeff Dyer, PhD, has decided to resign from its Board of Directors, effective immediately. "On behalf of our Board and PolarityTE's management team, we thank Jeff for his service and longstanding commitment to the Company," stated Richard Hague, Chief Executive Officer of PolarityTE.  "We greatly appreciate the leadership and insight that Jeff has provided over the past five and a half years as we purs

    9/8/22 8:30:00 AM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

    SAN DIEGO--(BUSINESS WIRE)--​Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra

    2/23/21 4:05:00 PM ET
    $VIE
    $PTE
    $RVNC
    Major Pharmaceuticals
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Pharmaceutical Preparations

    $PTE
    Financials

    Live finance-specific insights

    View All

    PolarityTE Reports Second Quarter 2022 Financial Results and Provides Business Update

    PolarityTE to host conference call and webcast today, August 11, 2022, at 4:30 p.m. ET SALT LAKE CITY, Aug. 11, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended June 30, 2022. Recent Business and Financial UpdatesIn January 2022, PolarityTE was advised by the U.S. Food and Drug Administration (FDA) that it could conduct human clinical trials under PolarityTE's investigational new drug application (IND

    8/11/22 4:05:00 PM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PolarityTE to Report Q2 2022 Financial Results on August 11, 2022

    SALT LAKE CITY, Aug. 1, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) today announced that it will report results for the quarter ended June 30, 2022, by press release on Thursday, August 11, 2022, at approximately 4:05 p.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on August 11, 2022, at 4:30 p.m. Eastern Time. The conference call can be accessed by calling 1-800-207-0148 with passcode 893469 and referencing "PolarityTE Second Quarter 2022 Business Update and Financial Results." A webcast of the conference call can be accesse

    8/1/22 8:00:00 AM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Polarity TE spins off IBEX Preclinical Research contract research organization

    Dr. Josh Packer acquires IBEX and becomes CEO; maintains existing surgical research team LOGAN, Utah, May 26, 2022 /PRNewswire-PRWeb/ -- IBEX Preclinical Research, Inc., a trusted outsourcing partner and provider of preclinical surgical and toxicological studies in a variety of laboratory animal species, announced that it has been acquired by Josh Packer, DVM. IBEX provides in-vivo research services ranging from relatively simple single-dose pharmacokinetic studies to more complex projects requiring surgical instrumentation. Conducting both GLP and non-GLP non-clinical testing, IBEX supports life science, medical device companies and researchers that specialize in orthopedics, neurosurgical,

    5/26/22 11:15:00 AM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PTE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by PolarityTE Inc. (Amendment)

    SC 13G/A - POLARITYTE, INC. (0001076682) (Subject)

    2/14/23 11:11:43 AM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by PolarityTE Inc.

    SC 13G - POLARITYTE, INC. (0001076682) (Subject)

    8/23/22 11:30:24 AM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed

    SC 13G - POLARITYTE, INC. (0001076682) (Subject)

    2/16/21 5:19:31 PM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PTE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PolarityTE Announces Entry Into a Letter of Intent For Acquisition of the Company

    SALT LAKE CITY, Dec. 27, 2022 /PRNewswire/ --  PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials (the "Company"), today announced that it signed a non-binding letter of intent (the "LOI") with Michael Brauser ("Brauser") for him to make an offer to acquire 100% of the outstanding equity interests of the Company at a proposed offering price of $1.03 per common share, which would be paid entirely in cash. As of December 23, 2022, there were 7,256,786 shares of the Company's common stock outstanding and unvested restricted stock units covering an additional 256,457 common shares. 

    12/27/22 8:30:00 AM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PolarityTE Reports Third Quarter 2022 Financial Results and Provides Business Update

    SALT LAKE CITY, Nov. 10, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended September 30, 2022. Recent Business and Financial UpdatesAt the end of April 2022, PolarityTE began enrollment in its Phase III randomized controlled trial (RCT), which is a pivotal study under its open IND for SkinTE®. The Company estimates that it may be able to complete enrollment of 100 subjects sometime in the first six mon

    11/10/22 4:30:00 PM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    PolarityTE Confirms Receipt of Unsolicited, Non-Binding Offer to Acquire the Company

    SALT LAKE CITY, Nov. 9, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials, today confirmed that on November 1, 2022, it received an unsolicited, non-binding offer (followed by an amended offer on November 8, 2022) from Michael Brauser to acquire all of the outstanding common stock of the Company not owned by him for $1.25 per share in cash. The offer is subject to various contingencies, including, among others, (1) settlement with warrant holders and satisfactory negotiations with insiders with change of control agreements, (2) minimum tender conditions, (3) a sixty-day due diligence period, and (4) satisfacti

    11/9/22 8:00:00 AM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care